|
1
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
a randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: the PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar
|
|
4
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hopfner R, Mousli M, Jeltsch JM, Voulgaris
A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C: ICBP90, a
novel human CCAAT bonding protein, involved in the regulation of
topoisomerase II alpha expression. Cancer Res. 60:121–128.
2000.PubMed/NCBI
|
|
6
|
Mousli M, Hopfner R, Abbady AQ, Monté D,
Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a
new family of proteins with an expression that is deregulated in
cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Unoki M, Nishidate T and Nakamura Y:
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Unoki M, Daigo Y, Koinuma J, Tsuchiya E,
Hamamoto R and Nakamura Y: UHRF1 is a novel diagnostic marker of
lung cancer. Br J Cancer. 103:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crnogorac-Jurcevic T, Gangeswaran R,
Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W,
Campbell F, Brentnall TA, et al: Proteomic analysis of chronic
pancreatitis and pancreatic adenocarcinoma. Gastroenterology.
129:1454–1463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oba-Shinjo SM, Bengtson MH, Winnischofer
SM, Colin C, Vedoy CG, de Mendonça Z, Marie SK and Sogayar MC:
Identification of novel differentially expressed genes in human
astrocytomas by cDNA representational difference analysis. Brain
Res Mol Brain Res. 140:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lorenzato M, Caudroy S, Bronner C, Evrard
G, Simon M, Durlach A, Birembaut P and Clavel C: Cell cycle and/or
proliferation markers: what is the best method to discriminate
cervical high-grade lesions? Hum Pathol. 36:1101–1107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Unoki M, Kelly JD, Neal DE, Ponder BA,
Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for
diagnosis and the prognosis of bladder cancer. Br J Cancer.
101:98–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Unoki M, Brunet J and Mousli M: Drug
discovery targeting epigenetic codes: the great potential of UHRF1,
which links DNA methylation and histone modifications, as a drug
target in cancers and toxoplasmosis. Biochem Pharmacol.
78:1279–1288. 2009. View Article : Google Scholar
|
|
14
|
Arima Y, Hirota T, Bronner C, Mousli M,
Fujiwara T, Niwa S, Ishikawa H and Saya H: Down-regulation of
nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage
checkpoint signals contributes to cell cycle arrest at G1/S
transition. Genes Cells. 9:131–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trotzier MA, Bronner C, Bathami K, Mathieu
E, Abbady AQ, Jeanblanc M, Muller CD, Rochette-Egly C and Mousli M:
Phosphorylation of ICBP90 by protein kinase A enhances
topoisomerase II alpha expression. Biochem Biophys Res Commun.
319:590–595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bostick M, Kim JK, Estève PO, Clark A,
Pradhan S and Jacobsen SE: UHRF1 plays a role in maintaining DNA
methylation in mammalian cells. Science. 317:1760–1764. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arita K, Ariyoshi M, Tochio H, Nakamura Y
and Shirakawa M: Recognition of hemi-methylated DNA by the SRA
protein UHRF1 by a base-flipping mechanism. Nature. 455:818–821.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Avvakumov GV, Walker JR, Xue S, Li Y, Duan
S, Bronner C, Arrowsmith CH and Dhe-Paganon S: Structural basis for
recognition of hemi-methylated DNA by the SRA domain of human
UHRF1. Nature. 455:822–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashimoto H, Horton JR, Zhang X, Bostick
M, Jacobsen SE and Cheng X: The SRA domain of UHRF1 flips
5-methylcytosine out of the DNA helix. Nature. 455:826–829. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharif J, Muto M, Takebayashi S, Suetake
I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T,
Okamura K, et al: The SRA protein Np95 mediates epigenetic
inheritance by recruiting Dnmt1 to methylated DNA. Nature.
450:908–912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JK, Estève PO, Jacobsen SE and Pradhan
S: UHRF1 binds G9a and participates in p21 transcriptional
regulation in mammalian cells. Nucleic Acids Res. 37:493–505. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin W, Chen L, Chen Y, Xu SG, Di GH, Yin
WJ, Wu J and Shao ZM: UHRF1 is associated with epigenetic silencing
of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat.
123:359–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meilinger D, Fellinger K, Bultmann S,
Rothbauer U, Bonapace IM, Klinkert WE, Spada F and Leonhardt H:
Np95 interacts with de novo DNA methyltransferases, Dnmt3a and
Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter
in embryonic stem cells. EMBO Rep. 10:1259–1264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abbady AQ, Bronner C, Bathami K, Muller
CD, Jeanblanc M, Mathieu E, Klein JP, Candolfi E and Mousli M: TCR
pathway involves ICBP90 gene down-regulation via E2F binding sites.
Biochem Pharmacol. 70:570–579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Distler P and Holt PR: Are right- and
left-sided colon neoplasms distinct tumors? Dig Dis. 15:302–311.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Birkenkamp-Demtroder K, Olesen SH,
Sørensen FB, et al: Differential gene expression in colon cancer of
the caecum versus the sigmoid and rectosigmoid. Gut. 54:374–384.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry
N and Iacopetta B: Association of tumour site and sex with survival
benefit from adjuvant chemotherapy in colorectal cancer. Lancet.
355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kapiteijn E, Liefers GJ, Los LC, et al:
Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol.
195:171–178. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fric P, Sovová V, Sloncová E, Lojda Z,
Jirásek A and Cermák J: Different expression of some molecular
markers in sporadic cancer of the left and right colon. Eur J
Cancer Prev. 9:265–268. 2000. View Article : Google Scholar : PubMed/NCBI
|
